Begüm Bektas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Begüm Bektas has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Canan Üçışık
Department of Infectious Diseases and Clinical Microbiology, İstanbul Medeniyet University Göztepe Training and Research Hospital, İstanbul, Turkey
1 shared publication - Fatma Yılmaz Karadağ
Department of Infectious Diseases and Clinical Microbiology, Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital, University of Health Sciences, 34000 İstanbul, Türkiye
1 shared publication - Havva Keskin
ANKARA ÜNİVERSİTESİ, TIP FAKÜLTESİ, DAHİLİ TIP BİLİMLERİ BÖLÜMÜ, İÇ HASTALIKLARI ANABİLİM DALI
1 shared publication - Pınar Ergen
Istanbul Medeniyet University Faculty of Medicine
1 shared publication - Yasemin Cag
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, İstanbul Medeniyet University, İstanbul, Turkiye
1 shared publication - Özlem Aydın
Istanbul Medeniyet Univ, Goztepe Training & Res Hosp, Clin Infect Dis & Clin Microbiol, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 28 October 2022
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 22 (3) , 426-435
Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV
Background: People living with HIV need to use antiretroviral therapy throughout their lives. Objectives: Studies on the efficacy and safety of dual therapy are limited in Turkey. We sought to evaluate the treatment efficacy and side effects among patients who were given a combination of dolutegravir (DTG) and lamivudine (3TC) as a maintenance therapy. Methods: This retrospective, single-centre study included individuals with viral suppression who were older than 18 years of age, living with HIV, switched from a combination antiretroviral therapy regimen to DTG-3TC dual therapy, and followed up for at least 6 months. Results: The study included 63 patients living with HIV. The median age was 42 years (interquartile range (IQR): 36-51 years). The median follow-up under the DTG-3TC regimen was 10.4 months (7.1-16.0 months). In the course of dual therapy, no patients developed any serious adverse effects that would necessitate a therapy switch, but virological blips were seen in two patients. Two patients lost their lives, with one dying from suicide and one dying from respiratory failure associated with the underlying chronic obstructive pulmonary disease. Conclusion: The DTG-3TC dual-therapy regimen is a promising and effective therapy that can be used as a treatment of choice for eligible patients. Keywords: Dolutegravir; lamivudine; dual; antiretroviral therapy; efficacy.
- 28 October 2022
- Published by African Journals Online (AJOL) in African Health Sciences
- Vol. 22 (3) , 426-435
Open AccessEvaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV
Background: People living with HIV need to use antiretroviral therapy throughout their lives. Objectives: Studies on the efficacy and safety of dual therapy are limited in Turkey. We sought to evaluate the treatment efficacy and side effects among patients who were given a combination of dolutegravir (DTG) and lamivudine (3TC) as a maintenance therapy. Methods: This retrospective, single-centre study included individuals with viral suppression who were older than 18 years of age, living with HIV, switched from a combination antiretroviral therapy regimen to DTG-3TC dual therapy, and followed up for at least 6 months. Results: The study included 63 patients living with HIV. The median age was 42 years (interquartile range (IQR): 36-51 years). The median follow-up under the DTG-3TC regimen was 10.4 months (7.1-16.0 months). In the course of dual therapy, no patients developed any serious adverse effects that would necessitate a therapy switch, but virological blips were seen in two patients. Two patients lost their lives, with one dying from suicide and one dying from respiratory failure associated with the underlying chronic obstructive pulmonary disease. Conclusion: The DTG-3TC dual-therapy regimen is a promising and effective therapy that can be used as a treatment of choice for eligible patients. Keywords: Dolutegravir; lamivudine; dual; antiretroviral therapy; efficacy.